Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Invested Capital (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Invested Capital for 15 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 68.95% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, down 68.95%, and an annual FY2024 reading of $11.1 million, down 12.44% over the prior year.
  • Invested Capital was $4.2 million for Q3 2025 at BioRestorative Therapies, down from $7.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $20.2 million in Q1 2022 and bottomed at -$4.8 million in Q3 2021.
  • Average Invested Capital over 5 years is $10.5 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Invested Capital soared 914.25% in 2021, then crashed 68.95% in 2025.
  • Year by year, Invested Capital stood at $10.8 million in 2021, then surged by 46.03% to $15.8 million in 2022, then dropped by 20.27% to $12.6 million in 2023, then dropped by 12.44% to $11.1 million in 2024, then tumbled by 62.22% to $4.2 million in 2025.
  • Business Quant data shows Invested Capital for BRTX at $4.2 million in Q3 2025, $7.4 million in Q2 2025, and $9.3 million in Q1 2025.